SCHEMBL6934348

SCHEMBL6934348

C/C(=N/OCCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccc(-c2ccccn2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 15/20 0.78
FFAR1 O14842 4/20 0.49
RXRA P19793 2/20 0.49
RARG P13631 1/20 0.49
ESR1 P03372 1/20 0.47
MPC2 O95563 1/20 0.47
CYP2C8 P10632 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP3A4 P08684 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1131019 1.00 PPARG (0.78) PPARGFFAR1RXRARARGESR1
Hydrochloric Acid SCHEMBL8446836 0.99 PPARG (0.77) PPARGFFAR1RXRARARGESR1
SCHEMBL8448406 0.90 PPARG (0.66) PPARGFFAR1RXRARARGESR1
SCHEMBL6898656 0.89 PPARG (0.81) PPARGFFAR1MPC2CYP2C8CYP2C9
SCHEMBL6899309 0.89 PPARG (0.81) PPARGFFAR1MPC2CYP2C8CYP2C9
SCHEMBL8309657 0.89 PPARG (0.76) PPARGFFAR1MPC2CYP2C8CYP2C9
SCHEMBL8309658 0.89 PPARG (0.76) PPARGFFAR1MPC2CYP2C8CYP2C9
SCHEMBL6898699 0.88 PPARG (1.00) PPARGFFAR1RXRARARGCYP3A4
SCHEMBL6898697 0.88 PPARG (1.00) PPARGFFAR1RXRARARGCYP3A4
SCHEMBL8114088 0.87 PPARG (0.69) PPARGFFAR1RXRAMPC2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6150371-A WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE SANKYO COMPANY, LIMITED (JP) 2000-11-21 US claimed
EP-0916651-B1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES SANKYO CO (JP) 2003-10-15 EP disclosed
US-6150371-A WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE SANKYO COMPANY, LIMITED (JP) 2000-11-21 US disclosed
US-6103907-A ALDOSE REDUCTASE INHIBITING ANTIDIABETIC AGENT SANKYO COMPANY, LIMITED (JP) 2000-08-15 US disclosed
EP-0953355-A1 REMEDY FOR AUTOIMMUNE DISEASES Sankyo Company, Limited (JP) 1999-11-03 EP disclosed
EP-0916651-A1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 1999-05-19 EP disclosed